619 material Form 8-K filings that 507 companies we cover made with the SEC in December 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Texas Community Bancshares' board approved a new stock repurchase program allowing the company to buy back up to 144,364 shares, about 5% of its outstanding common stock as of December 16, 2025. The company also said it had completed the repurchase of 153,083 shares under the prior program as of that date.
New program authorizes repurchases of up to 144,364 shares, about 5% of outstanding common stock as of December 16, 2025.
Company completed repurchase of 153,083 shares under the prior program as of December 16, 2025.
Repurchases may be made through open market purchases, a Rule 10b5-1 trading plan, or privately negotiated transactions; the exact number is not guaranteed and the program may be suspended or discontinued at any time.
Green Brick Partners amended its $330 million credit agreement on December 10, 2025, reducing interest rate spreads and extending all commitments to December 14, 2028. On December 11, 2025, its board authorized a new repurchase plan of up to $150.0 million that starts after the existing $100.0 million program is exhausted, with repurchased shares to be retired.
December 10, 2025: Thirteenth Amendment to the Credit Agreement with Flagstar Bank, N.A. as administrative agent; total commitments remain at $330 million
Spreads reduced on the SOFR and base rate; maturity of all commitments extended to December 14, 2028
December 11, 2025: board authorized up to $150.0 million in new share repurchases, with no time deadline, to begin after the prior $100.0 million program is used up
Vir Biotechnology granted Norgine Pharma UK Limited an exclusive license for commercial rights to its tobevibart and elebsiran combination for chronic hepatitis delta in Europe, Australia and New Zealand. Vir will receive an initial reimbursement of EUR 55 million, is eligible for up to EUR 495 million in milestones, and will earn royalties on net sales in that territory, while the companies share ECLIPSE trial costs. The company says the agreement extends its current cash runway into the fourth quarter of 2027.
Initial reimbursement payment of EUR 55 million to Vir, with closing for certain non-US jurisdictions subject to regulatory approval
Eligible for up to EUR 495 million in clinical, regulatory and sales milestones, plus tiered mid-teen to high-twenties percent royalties on net sales in the licensed territory
Norgine to contribute approximately 25% of go-forward external costs for the ECLIPSE 1, 2 and 3 trials
Vir retains commercial rights in the United States and other markets outside the Greater China Territory; company expects cash runway into Q4 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.